sorafenib has been researched along with Body Weight in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, D; Chen, X; Kang, M; Wang, Y; Zhu, L | 1 |
| Ahmed, AR; Alaaeldin, E; Allam, S; Elsadek, BE; Elsayed, MM; Mostafa, ME; Sarhan, HA; Shaykoon, MS | 1 |
| Han, JK; Kim, JH; Lee, HJ; Lee, S; Moon, H | 1 |
| Chen, M; Cheng, AL; Dutcus, C; Finn, R; Han, KH; Hayato, S; Ikeda, K; Kobayashi, M; Kudo, M; Kumada, H; Mody, K; Okusaka, T; Piscaglia, F; Qin, S; Ren, M; Ren, Z; Sung, M; Tamai, T; Wyrwicz, L; Yoon, JH | 1 |
| Bertone, V; Giglio, V; Maric, I; Vaccarone, R; Vecchio, G; Viale, M | 1 |
| Andersen, KJ; Hamilton-Dutoit, S; Kannerup, AS; Knudsen, AR; Ladekarl, M; Mortensen, FV; Nyengaard, JR; Sasanuma, H | 1 |
| Prado, CM | 1 |
| Andersen, KJ; Hamilton-Dutoit, S; Kannerup, AS; Knudsen, AR; Ladekarl, M; Mortensen, FV; Nyengaard, JR | 1 |
| Chow, PK; Chung, A; Huynh, H; Lam, IW; Lee, JW; Lew, GB; Ngo, VC; Ong, HS; Soo, KC | 1 |
1 review(s) available for sorafenib and Body Weight
| Article | Year |
|---|---|
Body composition in chemotherapy: the promising role of CT scans.
Topics: Anthracyclines; Body Composition; Body Weight; Chemotherapy, Adjuvant; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Muscle, Skeletal; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Reproducibility of Results; Sorafenib; Sunitinib; Tomography, X-Ray Computed | 2013 |
8 other study(ies) available for sorafenib and Body Weight
| Article | Year |
|---|---|
Assessing the effectiveness of camrelizumab plus apatinib versus sorafenib for the treatment of primary liver cancer: a single-center retrospective study.
Topics: Body Weight; Humans; Liver Neoplasms; Retrospective Studies; Sorafenib | 2023 |
Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Body Weight; Carcinoma, Hepatocellular; Cell Proliferation; Drug Compounding; Drug Design; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Liver; Liver Neoplasms; Male; Nanotubes, Carbon; Niacinamide; Rats, Wistar; Sorafenib; Spectroscopy, Fourier Transform Infrared; Static Electricity | 2019 |
Combined treatment of sorafenib and doxorubicin-loaded microbubble-albumin nanoparticle complex for hepatocellular carcinoma: A feasibility study.
Topics: Albumins; Animals; Body Weight; Carcinoma, Hepatocellular; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Interactions; Feasibility Studies; Humans; Liver Neoplasms; Microbubbles; Nanoparticles; Rats; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Body Weight; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Quinolines; Sorafenib; Treatment Outcome | 2021 |
Cyclodextrin polymers as nanocarriers for sorafenib.
Topics: Animals; Apoptosis; Body Weight; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cellulose; Circular Dichroism; Cyclodextrins; Drug Carriers; Female; Humans; Inhibitory Concentration 50; Kinetics; Mice, Nude; Nanoparticles; Organ Specificity; Solubility; Sorafenib | 2018 |
Sorafenib inhibits liver regeneration in rats.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Bilirubin; Body Weight; Cell Proliferation; Hepatectomy; Ki-67 Antigen; Liver; Liver Regeneration; Niacinamide; Organ Size; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Wistar; Sorafenib; Time Factors | 2013 |
Postoperative but not preoperative treatment with sorafenib inhibits liver regeneration in rats.
Topics: Animals; Body Weight; Cell Proliferation; Hepatectomy; Hepatocytes; Liver Regeneration; Niacinamide; Organ Size; Phenylurea Compounds; Postoperative Period; Protein Kinase Inhibitors; Rats; Rats, Wistar; Sorafenib | 2014 |
Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Agents; Base Sequence; Benzenesulfonates; Body Weight; Disease Models, Animal; Disease Progression; Exons; Gastrointestinal Stromal Tumors; Humans; MAP Kinase Signaling System; Mice; Mice, SCID; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyridines; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |